Jounce Therapeutics

Research Associate / Senior Research Associate, Discovery

Job ID
2021-1270
Category
Research & Development
Job Location
US-MA-Cambridge

Role / Responsibilities

Jounce is looking for a Research Associate/Senior Research Associate Scientist specializing in In Vitro biology to join our Discovery Immuno-Oncology team. The successful candidate will be a highly motivated bench scientist committed to elucidating the mechanism of action, and enabling the development, of novel cancer immunotherapeutic biologics. They will generate data to support key decisions for project teams and actively participate in the interpretation of data and design of experiments. They will have the opportunity to work independently and collaboratively to advance portfolio programs in a dynamic and fast-paced environment.

 

Responsibilities:

  • Performance of immune cell-based in vitro assays, including primary immune cell isolation, mammalian cell culture, multi-color flow cytometry, ELISA, multiplex technologies and proliferation assays;
  • Data analysis and thorough documentation of work in the company’s eLN system;
  • Presentation of results in team meetings and other group settings;
  • Work cross-functionally as part of internal multi-disciplinary project teams;
  • Maintain a safe and clean laboratory environment following all precautions required for a BSL2/BSL2+ setting.

Qualifications

  • B.S./M.S. in biology, biochemistry, immunology or related discipline with 1-2 years relevant experience (industry preferred);
  • A working knowledge of fundamental immunological principles;
  • Experience with cell-based functional assays using primary immune cells, such as MLR, and T cell activation/proliferation assays strongly preferred;
  • Hands-on experience with primary human immune cell culture and differentiation, flow cytometry cell phenotyping and multiplex ELISA systems strongly preferred;
  • Ability to follow defined procedures and protocols, and strong attention to detail;
  • Willingness to learn new research methods and a desire for continued learning and development;
  • Excellent organization and record-keeping skills;
  • Demonstrated accountability and responsibility for own work; and
  • Ability to work both independently and in a team setting.

Statement

Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.

Company Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce currently has four development-stage programs, two of which are clinical-stage: vopratelimab, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor intended for combination use with Jounce’s broader pipeline. Vopratelimab is currently being assessed in a Phase 2 clinical trial, EMERGE, and Jounce plans to initiate an additional Phase 2 biomarker trial using TISvopra for patient selection, SELECT, to assess vopratelimab in combination with JTX-4014. Jounce’s IND-enabling preclinical programs include JTX-8064, a LILRB2 receptor antagonist and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that was recently partnered with Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed